HCV E2 Immunogen Nanoparticle Vaccine Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HCV vaccine development faces challenges in eliciting a broadly protective immune response due to the high genetic diversity of HCV genotypes and rapid mutation, leading to immune escape, and existing vaccines have limited neutralization breadth and are unable to prevent liver cancer or reinfection.
Innovation Solution
Modified HCV E2 ectodomain polypeptides with truncated VR2 disordered regions and deleted β-sandwich loops are redesigned and displayed on self-assembling nanoparticles to enhance immune response, focusing on broadly neutralizing antibodies and reducing binding to non-neutralizing antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional HCV E2 immunogens are used, then vaccine compositions can be developed, but the immunogens have limited neutralization breadth and fail to elicit broadly protective immune response due to HCV genetic diversity and mutation
Solution Approach 1:
The E2 ectodomain is segmented by removing variable regions (VR1, VR2, VR3) and retaining only the conserved core domain, which contains the essential neutralizing epitopes. This segmentation eliminates variable regions that limit neutralization breadth while preserving the conserved protective epitopes, thereby achieving both broad adaptability and reliable protection.
Solution Approach 2:
The variable regions (VR1, VR2, VR3) that contribute to immune escape and limit neutralization breadth are extracted and removed from the E2 ectodomain. This extraction leaves only the conserved core domain with essential neutralizing epitopes, enabling the immunogen to elicit broadly protective immune responses across diverse HCV genotypes.
2Stability of the object's composition
If variable regions are retained in E2 immunogen, then immunogen structure is complete, but rapid mutation in variable regions leads to immune escape and reduced vaccine effectiveness
Solution Approach 1:
The variable regions (VR1, VR2, VR3) that are prone to rapid mutation and immune escape are extracted and removed from the E2 ectodomain. This extraction eliminates the source of variability while maintaining the stable conserved core domain structure, thereby preventing immune escape and ensuring vaccine effectiveness across different HCV strains.
Solution Approach 2:
The immunogen design changes the compositional parameters by retaining only the conserved core domain with essential neutralizing epitopes and excluding variable regions. This parameter change transforms the immunogen from a complete E2 ectodomain to a truncated core domain that is stable against mutation and resistant to immune escape.
3Quantity of substance
If full-length E2 ectodomain is used, then all epitopes are present, but yield and purity of the immunogen are reduced
Solution Approach 1:
The variable regions and non-essential portions are extracted and removed from the full-length E2 ectodomain, retaining only the conserved core domain with essential neutralizing epitopes. This extraction reduces the overall size and complexity of the immunogen, thereby improving expression yield and purification efficiency while preserving the quantity of essential epitopes.
Solution Approach 2:
The E2 ectodomain is segmented into variable regions and conserved core domain, with only the essential core domain containing neutralizing epitopes being retained. This segmentation improves productivity by focusing production on the most critical epitopic regions, enhancing both yield and purity of the functional immunogen.
Data Source
AI summary
The present invention provides novel engineered HCV E2 polypeptide immunogens and related vaccine compositions that display the engineered E2 polypeptides. The invention also provides methods of using such immunogens and vaccine compositions in various therapeutic applications, e.g., for preventing or treating HCV infections.